ROSSARINSERossari Biotech LimitedMediumNeutral
Announced Mon, 27 Apr · 18:33 IST

Board okays FY26 results, Rs 0.50 dividend, new Independent Director

Management Changes View source PDF

ROSSARI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-7.4%1-day move
₹505.20
prior close
₹504.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.1-4.5-3.8-5.0-7.4-5.6-5.0-4.8-2.9+7.7+0.4+3.5+3.1-0.1
Up moveDown movePending
AI summary

Board approved FY26 audited results: consolidated revenue Rs 23,963.65M (up 15% YoY), PAT Rs 1,492.13M (up 9%). Final dividend of Re 0.50/share (25%) recommended. Mr. Udeypaul Singh Gill appointed as Independent Director for 3 years from April 28. Capacity expansion rescheduled to phased rollout over 2 years; new R&D facility set up in Navi Mumbai. 8,250 ESOP shares allotted at Rs 425.

Likely market impact

Solid revenue and profit growth with a modest dividend. Capacity project delay may temper capex excitement, but strategic intent and R&D push remain intact.